Chinese Medicine Innovation Dragon Hair Wei! 3 exclusive proprietary Chinese medicines sold tens of billions, 10 new types of 1 drugs sprinted, and 2 billion varieties grabbed the first imitation

A few days ago, the official website of CDE showed that the listing application of Qihuang Mingmu capsule submitted by Yiling Pharmaceutical in the new drug class 1.

With 13 patented new drugs in hand, 3 exclusive proprietary Chinese medicines sold for 10 billion

Relying on the self-contained "theory of network disease" Traditional Chinese medicine theory, Yiling Pharmaceutical has been approved 13 patented new drugs, including macaroni capsules/tablets, Ginsengsong Yangxin capsules, alfalfa qiangxin capsules, Lianhua Qingyi capsules/granules/tablets, Jinlida granules, Yangzheng anti-accumulation capsules, Xia Liqi capsules, Lianhua qing cough tablets, anti-depression and anti-annoyance capsules, kidney and heart-nourishing tablets, etc.

Lianhua Qingpeng capsules/granules are the core products of Ling Pharmaceutical, which are the national medical insurance Class A and national basic drugs, and have been recommended

In 2021, among the top 10 generic names of terminal cold proprietary Chinese medicines in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions), Lianhua Qingyi dominated

In recent years, China's three major terminals and 6 major markets lianhua qing plague sales (: 10,000 yuan)

Source: Intranet Database

Tongxinluo Capsules, Ginsengsong Yangxin Capsules, and Qiqi Qiangxin Capsules are the three major fist products of Ling Pharmaceutical in the field of cardiovascular chinese patent medicine, and they are all exclusive, national medical insurance Class A, national basic drug species, and the "main battlefield" is in the hospital market (public hospital + public primary medical care).

Tongxin capsule has the effect of invigorating blood and relieving pain, and is used for coronary heart disease, angina is a lack of heart qi, and blood stasis obstruction

In recent years, the sales of macaroni network in China's three major terminal markets (: 10,000 yuan)

Source: Intranet Database

GinsengSong Yangxin Capsule has the effect of nourishing qi and nourishing yin, invigorating blood circulation, purifying the heart and calming the nerves, and is used to treat coronary heart disease

In recent years, China's three major terminals and 6 major markets ginseng pine heart sales (: 10,000 yuan)

Source: Intranet Database

Amaranth Heart Strengthening Capsule has the effect of improving temperature and yang, activating blood circulation, water and swelling, and is used for mild and moderate congestive heart failure caused by coronary heart disease and hypertension

In recent years, China's three major terminals and 6 major markets Alfalfa Qiangxin sales (: 10,000 yuan)

Source: Intranet Database

In the field of diabetes treatment, Jinlida granules are the exclusive varieties of Yiling Pharmaceutical, which is a national medical insurance class B and a national basic drug, which has the effect of nourishing yin and healthy spleen, and is used for type 2 diabetes qi and yin

Approved as a "bellwether", 6 innovative Chinese medicine drugs are on the way

As one of the leading innovative enterprises in traditional Chinese medicine, Yiling Pharmaceutical continues to increase its research and development efforts, focusing on the research and development

The performance report shows that in the first half of 2022, Ling Pharmaceutical invested 385 million yuan in research and development, accounting for 6.

2019H1-2022H1 R&D investment of Yiling Pharmaceutical (: 100 million yuan)

Source: Company Announcement

Since 2020, 16 new Chinese medicine drugs (in terms of drug name + enterprise, excluding APIs) have been approved for listing, covering anti-tumor, respiratory system, nervous system, gynecology, orthopedics and other therapeutic fields

New Chinese medicine drugs approved for marketing since 2020 (excluding APIs)

Source: MED2.

In terms of the research and development of innovative Chinese medicine drugs, the company currently has 6 new Chinese medicine drugs in the clinical and above stages of approval, of which Qihuang Mingmu Capsules have submitted a listing application for the treatment of diabetic retinopathy

Paralysis tablets (rheumatoid arthritis), chai huang choleretic capsules (chronic cholecystitis), and Yuping tong tablets (persistent allergic rhinitis) are undergoing phase III clinical trials

Yiling Pharmaceutical is researching new chinese medicine drugs

Source: Minnet China Drug Clinical Trial Publicity Library

In addition, Yiling Pharmaceutical is also actively and continuously carrying out post-market re-evaluation and secondary development of listed Chinese medicine varieties, among which Yangzheng Anti-accumulation Capsules are applying for new indications

13 varieties have been evaluated, and the first chemical drug class 1 new drug is about to be produced

While carrying out innovative Chinese medicine research and development, Yiling Pharmaceutical is also actively laying out chemical drugs, biological drugs and health industries, and building a pharmaceutical and health industry pattern
in which patented Chinese medicine, chemical and biological drugs, and health industries develop in synergy and promote each other.

In terms of innovative chemical drugs, Yiling Pharmaceutical has 4 new class 1 drugs into the clinical stage, of which anilineprofen injection has made the fastest progress, which is a non-steroidal analgesic, which is intended to be used for postoperative pain, various cancer pain, low back pain, gout attacks, neuralgia, etc
.
Its postoperative moderate to severe pain indications have completed phase III clinical trials and are about to declare NDA
.

Yiling Pharmaceutical is developing innovative drugs for chemical drugs

Source: Minnet China Drug Clinical Trial Publicity Library

In terms of chemical generic drugs, 13 varieties of Ling Pharmaceutical have passed or are regarded as consistency evaluations, focusing on systemic anti-infective drugs, digestive and metabolic drugs, cardiovascular and cerebrovascular system drugs and other fields, of which ciprofloxacin hydrochloride tablets are the first to be evaluated
.

To Ling Pharmaceutical Consistency Evaluation Declaration

Source: MED2.
0 China Drug Review Database

In addition, 3 varieties submitted supplementary applications for consistency evaluation and are under review, and 6 varieties were produced in new classifications, of which sakuba valsartan sodium tablets were not approved for the first time, and the global sales of the original research products reached 3.
548 billion US dollars in 2021, while the sales in the 6 major markets of China's three terminals exceeded 2 billion yuan, an increase of 127.
6%
year-on-year.

In the overseas market, Yiling Pharmaceutical has so far obtained FDA approval for 13 ADNA document numbers, of which paroxetine hydrochloride tablets, valacyclovir hydrochloride tablets, buspirone hydrochloride tablets, lisinopril tablets, lamotrizine extended-release tablets, acyclovir capsules and other varieties have not been reported to China
.